Advertisement
Research Article Free access | 10.1172/JCI113794
Department of Medicine, Veterans Administration West Side, Chicago, Illinois 60612.
Find articles by Kukreja, S. in: JCI | PubMed | Google Scholar
Department of Medicine, Veterans Administration West Side, Chicago, Illinois 60612.
Find articles by Shevrin, D. in: JCI | PubMed | Google Scholar
Department of Medicine, Veterans Administration West Side, Chicago, Illinois 60612.
Find articles by Wimbiscus, S. in: JCI | PubMed | Google Scholar
Department of Medicine, Veterans Administration West Side, Chicago, Illinois 60612.
Find articles by Ebeling, P. in: JCI | PubMed | Google Scholar
Department of Medicine, Veterans Administration West Side, Chicago, Illinois 60612.
Find articles by Danks, J. in: JCI | PubMed | Google Scholar
Department of Medicine, Veterans Administration West Side, Chicago, Illinois 60612.
Find articles by Rodda, C. in: JCI | PubMed | Google Scholar
Department of Medicine, Veterans Administration West Side, Chicago, Illinois 60612.
Find articles by Wood, W. in: JCI | PubMed | Google Scholar
Department of Medicine, Veterans Administration West Side, Chicago, Illinois 60612.
Find articles by Martin, T. in: JCI | PubMed | Google Scholar
Published November 1, 1988 - More info
A parathyroid hormone-related protein (PTHrP) has recently been isolated from tumors associated with hypercalcemia. In the present study, we tested the effects of neutralizing antisera to the PTHrP on serum calcium and urine cAMP in two animal models of malignancy-associated hypercalcemia. The animal models consisted of (a) a human squamous cell lung cancer and (b) a human laryngeal cancer, both serially carried in athymic mice. The antisera specifically reduced the elevated serum calcium and urinary cAMP levels in the tumor-bearing animals. We conclude that PTHrP plays a major role in the pathogenesis of malignancy-associated hypercalcemia.